N※N

Korro Bio Secures $85 Million in Funding for Epilepsy Treatment

  //stocks-investing.news-articles.net/content/202 .. 5-million-in-funding-for-epilepsy-treatment.html
  Published in Stocks and Investing on Monday, March 9th 2026 at 9:25 GMT by Seeking Alpha
      Locales: UNITED STATES, CANADA

SAN FRANCISCO, CA - March 9th, 2026 - Korro Bio, Inc. (KRRO) today announced the successful completion of an oversubscribed $85 million private placement. The financing round, led by RA Medical and Orbimed with participation from existing investors MPM Capital and EcoR1, signals strong confidence in the company's lead drug candidate, KB-101, and its potential to revolutionize the treatment of epilepsy.

The substantial influx of capital will be pivotal in funding a crucial Phase 3 clinical trial for KB-101, a novel therapeutic designed as an adjunctive therapy for focal seizures. This trial, slated to begin in the second quarter of 2026, represents a significant step towards potentially bringing a much-needed new treatment option to patients battling this debilitating neurological disorder.

Epilepsy: A Persistent Unmet Medical Need

Epilepsy affects over 65 million people worldwide, making it one of the most common neurological diseases globally. While numerous anti-epileptic drugs (AEDs) exist, a significant portion of patients - estimated to be around 30% - continue to experience uncontrolled seizures despite treatment. This lack of effective control profoundly impacts quality of life, leading to increased risk of injury, psychological distress, and even sudden unexpected death in epilepsy (SUDEP).

Focal seizures, which originate in one area of the brain, represent a substantial portion of all epilepsy cases. Current treatments often come with significant side effects, including fatigue, cognitive impairment, and mood disturbances. The need for therapies that offer improved efficacy and a better safety profile is paramount. KB-101 aims to address this gap, offering a potentially superior option for those who haven't found adequate relief with existing medications.

KB-101: A Novel Approach to Epilepsy Management

Korro Bio has remained tight-lipped regarding the precise mechanism of action of KB-101, but statements suggest it represents a novel approach. Unlike many existing AEDs that broadly suppress neuronal activity, KB-101 appears to target specific pathways involved in seizure generation, potentially minimizing off-target effects and improving tolerability. This targeted approach could be a key differentiator, allowing patients to achieve better seizure control with fewer side effects.

The Phase 3 trial will be a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of KB-101 when added to patients' existing AED regimens. The trial's success will be measured by a reduction in seizure frequency compared to the placebo group, as well as assessments of patient-reported outcomes and quality of life. Enrollment criteria are expected to focus on patients with focal seizures who have not responded adequately to currently available therapies.

Investor Confidence Fuels Advancement

The oversubscribed nature of the private placement underscores the strong belief investors have in Korro Bio's technology and the potential of KB-101. The participation of established healthcare investment firms like RA Medical, Orbimed, MPM Capital, and EcoR1 lends further credibility to the company and its mission.

"We are very excited about the strong support shown by both new and existing investors," stated Gary Jacobus, M.D., Chief Executive Officer of Korro Bio. "This financing enables us to accelerate the development of KB-101 and bring this potentially life-changing therapy to patients suffering from epilepsy."

Regulatory Pathway and Commercialization

If the Phase 3 trial yields positive results, Korro Bio plans to submit a New Drug Application (NDA) to the Food and Drug Administration (FDA) seeking approval to market KB-101. The timeline for regulatory review and potential commercial launch is typically lengthy, but the company is optimistic that KB-101 could reach patients in need within a few years of successful trial completion.

However, it's crucial to acknowledge the inherent risks associated with pharmaceutical development. The success of the Phase 3 trial is not guaranteed, and even with positive results, regulatory approval is not assured. Korro Bio's filings with the Securities and Exchange Commission (SEC) detail these risks, including potential manufacturing challenges, competition from other epilepsy treatments, and the possibility of unforeseen safety issues.

Despite these challenges, the $85 million funding round provides Korro Bio with the financial runway to execute its clinical development plan and move closer to delivering a potentially transformative therapy for the millions worldwide affected by epilepsy.